Matches in Wikidata for { <http://www.wikidata.org/entity/Q90030501> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q90030501 description "artículu científicu espublizáu n'avientu de 2018" @default.
- Q90030501 description "im Dezember 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90030501 description "scientific article published on 01 December 2018" @default.
- Q90030501 description "wetenschappelijk artikel" @default.
- Q90030501 description "наукова стаття, опублікована в грудні 2018" @default.
- Q90030501 name "Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months" @default.
- Q90030501 name "Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months" @default.
- Q90030501 type Item @default.
- Q90030501 label "Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months" @default.
- Q90030501 label "Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months" @default.
- Q90030501 prefLabel "Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months" @default.
- Q90030501 prefLabel "Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months" @default.
- Q90030501 P1104 Q90030501-7D4B15F8-DA20-4FA0-A095-3DC0D57620E2 @default.
- Q90030501 P1433 Q90030501-89115A93-FF60-48BD-90B9-5E8FA01D86B8 @default.
- Q90030501 P1476 Q90030501-53840A83-E231-4E91-8617-4BFDCFF1B2A6 @default.
- Q90030501 P2093 Q90030501-1CDB912E-6E22-430F-A1DC-13609D0694EC @default.
- Q90030501 P2093 Q90030501-1EEC00A7-9FCD-407D-AEEE-DB6782D76FB7 @default.
- Q90030501 P2093 Q90030501-3E49F597-643B-4690-96F2-C3B64A1989C1 @default.
- Q90030501 P2093 Q90030501-767BBE2F-0B3D-4167-8FA6-E5CE7C927930 @default.
- Q90030501 P2093 Q90030501-DEF946F1-1C73-4909-8F0C-8F08353ACE33 @default.
- Q90030501 P304 Q90030501-48B92D92-AB51-45DF-98F4-2D315BBDD0B8 @default.
- Q90030501 P31 Q90030501-8189FF35-3960-49D3-9E4C-27D05DABE609 @default.
- Q90030501 P356 Q90030501-2730F335-A187-4B26-BB77-D7E122CC29CF @default.
- Q90030501 P433 Q90030501-6D308FC0-1A71-48F5-9DF5-E5CA7A9CD567 @default.
- Q90030501 P478 Q90030501-B1238D97-1F58-459C-A0B2-C7ACEAF2BF4F @default.
- Q90030501 P50 Q90030501-362C8ED4-B6F2-4254-95FE-A975FC77FEF1 @default.
- Q90030501 P50 Q90030501-D9421500-F482-49A9-9096-EE2296630035 @default.
- Q90030501 P577 Q90030501-B5019DAA-48E0-409A-8F3E-3CA4A8A2F9B5 @default.
- Q90030501 P698 Q90030501-425442E3-50DF-4013-9CB1-BBFA4544DC14 @default.
- Q90030501 P356 BJOPHTHALMOL-2018-312944 @default.
- Q90030501 P698 30504490 @default.
- Q90030501 P1104 "+5" @default.
- Q90030501 P1433 Q13443571 @default.
- Q90030501 P1476 "Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months" @default.
- Q90030501 P2093 "Daniel Barthelmes" @default.
- Q90030501 P2093 "David Squirrell" @default.
- Q90030501 P2093 "Kelvin Teo" @default.
- Q90030501 P2093 "Mark C Gillies" @default.
- Q90030501 P2093 "Mark Daniell" @default.
- Q90030501 P304 "1337-1341" @default.
- Q90030501 P31 Q13442814 @default.
- Q90030501 P356 "10.1136/BJOPHTHALMOL-2018-312944" @default.
- Q90030501 P433 "9" @default.
- Q90030501 P478 "103" @default.
- Q90030501 P50 Q40635714 @default.
- Q90030501 P50 Q51656753 @default.
- Q90030501 P577 "2018-12-01T00:00:00Z" @default.
- Q90030501 P698 "30504490" @default.